Welcome to our dedicated page for Oncotelic Therapeutics SEC filings (Ticker: OTLC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Oncotelic Therapeutics, Inc. filings document formal disclosures for a clinical-stage biopharmaceutical issuer with oncology, rare-disease, AI-enabled research and drug-delivery assets. Recent Form 8-K reports cover material definitive agreements, including the TechForce Robotics joint development and licensing framework for AI-enabled GMP robotic systems using the PDAOAI platform, the completed Lunai Bioworks asset transaction involving nose-to-brain delivery patents, and financing arrangements tied to convertible debt and warrants.
OTLC filings also describe capital-structure and governance matters, including a performance-based restricted stock agreement involving Series A Preferred Stock, common-stock conversion terms, secured-note collateral and warrant issuances. Other filings include annual-results exhibits, late annual-report notices on Form 12b-25, and furnished updates on GMP Bio interests, Sapu Nano's Deciparticle nanomedicine platform, everolimus toxicology data and pipeline disclosures.
Oncotelic Therapeutics, Inc. reported total assets of $394.8 million at June 30 2026, driven largely by a Level 3 fair value investment in its GMP Bio joint venture of $388.0 million and a Lunai Bioworks equity investment of $1.4 million.
For Q2 2026, the company generated $250,000 of service revenue and an operating loss of $843,565, but posted net income attributable to Oncotelic of $388,147 due mainly to a $1.1 million gain on derecognition of a non‑financial asset and a $300,000 gain on its Lunai investment. For the six months, it recorded a net loss of $1.9 million and operating cash outflow of $434,440, funded by $531,597 of net financing inflows including $500,000 in new convertible debt.
Oncotelic discloses negative working capital of about $16.4 million, total liabilities of $131.3 million (including a $111.6 million deferred tax liability), and substantial convertible and short‑term debt. Management states that recurring losses, limited recent fundraising and liquidity shortfall raise substantial doubt about its ability to continue as a going concern without additional capital.
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a 2026 Pacific Pier Note 2, a convertible promissory note with aggregate gross principal of $178,410. The note bears 12% annual interest, includes a 12% original issue discount, and matures on the earlier of one year from the agreement date, acceleration upon an Event of Default, or full prepayment.
The note is convertible into common stock at the lesser of a fixed $0.06 per share Conversion Price or 85% of the lowest traded price over the ten trading days before conversion, with adjustment for certain corporate events. Oncotelic also issued 500,000 commitment shares to Pacific Pier. Prepayment is permitted at any time prior to six months from the note date with notice, and upon an Event of Default the amount becomes immediately due in cash with default interest of 16% per annum. The issuance relies on a Section 4(a)(2) Securities Act exemption.
Fein Seymour Howard reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. granted its CRO/CMO, Seymour Howard Fein, 250 restricted stock units on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, and each preferred share is convertible into 1,000 common shares, contingent on performance and time-based vesting. Vesting requires an uplisting of the common stock to a national securities exchange by June 30, 2027 (or a later Board-approved date) and six months of continued service after the uplisting.
Oncotelic Therapeutics, Inc., a Delaware biotechnology company with no revenues, filed a Form D for an exempt offering under Rule 506(b). The company reports a Total Amount Sold of $711,840 USD in equity securities, including options, warrants and securities issuable upon exercise.
The securities consist of RSUs convertible into Series A preferred shares and then common stock, granted to directors, officers, employees and advisors as compensation for services. These RSUs are contingent on achieving specified corporate milestones. The notice indicates $0 USD remaining to be sold and finder’s fees of $0 USD. CEO Vuong Trieu signed the notice on behalf of the issuer.
KING STEVEN W reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics granted director Steven W. King 250 restricted stock units (RSUs) on July 10, 2026 at $0.00 per unit. Each RSU is subject to performance and time-based vesting and represents a contingent right to one share of Series A Convertible Preferred Stock, with each such share convertible into 1,000 common shares. The RSUs vest only if the company uplists its common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and he remains in service for six months after any such uplisting; following this grant he holds 250 RSUs directly.
Oncotelic Therapeutics, Inc. reports that on July 13, 2026 it delivered a corporate presentation to its employees, directors, officers and advisors. The presentation, referred to as the “Corporate Presentation,” is provided as Exhibit 99.1 to the current report.
The company states that the information furnished under Section 8.01, including Exhibit 99.1, is being furnished rather than filed for purposes of Section 18 of the Securities Exchange Act of 1934. It also clarifies that this information is not incorporated by reference into any Securities Act or Exchange Act filing, except where specifically referenced. The report is signed on behalf of the company by Vuong Trieu, Ph.D., its Chief Executive Officer.
Oncotelic Therapeutics, Inc. approved equity incentives for directors, officers, employees and advisors by granting an aggregate 17,796 restricted stock units (RSUs) under Restricted Stock Unit Award Agreements. Each RSU represents a contingent right to receive one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock.
The RSUs vest only if the company’s common stock is uplisted to a national stock exchange on or before June 30, 2027, or a later date if extended by the board, and the recipient continues service for six months after the uplisting. Otherwise, the RSUs automatically expire and are forfeited. Grants include 2,000 RSUs to CEO Vuong Trieu and 1,500 RSUs each to several senior executives. The awards are granted at no cost to recipients and rely on the private-offering exemption in Section 4(a)(2) of the Securities Act.
MAIDA ANTHONY E III reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics, Inc. reported that director and Chief Medical Officer – Translational Medicine Anthony E. Maida III received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026 at no cost. Each RSU settles into one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock. The RSUs are subject to performance and time-based vesting, becoming eligible upon an uplisting of the company’s common stock to a national securities exchange on or before June 30, 2027 (or a later Board-approved date) and the executive’s continued service for six months following the uplisting.
Oncotelic Therapeutics CBO Saund Saran received a grant of 1,500 restricted stock units on July 10, 2026. Each RSU represents a contingent right to one share of Series A Convertible Preferred Stock, which is convertible into 1,000 common shares, for up to 1,500,000 common shares if fully vested and converted. The RSUs are subject to performance and time-based vesting tied to an uplisting of the company’s common stock to a national securities exchange and continued service requirements.
Shah Amit B. reported acquisition or exercise transactions in this Form 4 filing.
Oncotelic Therapeutics CFO Amit B. Shah received a grant of 1,500 restricted stock units (RSUs) on July 10, 2026. Each RSU will settle into one share of Series A Convertible Preferred Stock, which is itself convertible into common stock, if performance and time-based vesting conditions tied to a national-exchange uplisting are satisfied.